Dogwood Therapeutics (NASDAQ:DWTX) Posts Earnings Results, Misses Expectations By $4.80 EPS

Dogwood Therapeutics (NASDAQ:DWTX) released its quarterly earnings results on Monday. The company reported ($6.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.49) by ($4.80), Zacks reports.

Dogwood Therapeutics Stock Performance

Shares of NASDAQ:DWTX traded down $0.65 during mid-day trading on Monday, hitting $4.99. 141,822 shares of the company traded hands, compared to its average volume of 1,909,165. The firm’s 50-day moving average price is $7.67. Dogwood Therapeutics has a 12-month low of $1.62 and a 12-month high of $29.28. The stock has a market cap of $6.65 million, a PE ratio of -0.76 and a beta of 2.07.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics, Inc is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia.